Search results
Results from the WOW.Com Content Network
Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. [4] The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. [7] [8] The medicine is given by infusion (drip) into a vein. [4] [9]
Sipavibart is an experimental medication under investigation for the prevention of COVID‑19 in people who are immunocompromised. [1] Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain. [1] [2]
The class I fusion proteins, a group whose well-characterized examples include the coronavirus spike protein, influenza virus hemagglutinin, and HIV Gp41, are thought to be evolutionarily related. [7] [86] The S2 region of the spike protein responsible for membrane fusion is more highly conserved than the S1 region responsible for receptor ...
Researchers at Boston’s Dana-Farber Cancer Institute are working on a drug that takes one of the virus’s most dangerous traits — its talent for mutation — and turns it back on itself.
It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein. [1] Self-amplifying means that the mRNA also carries instructions to make a protein called replicase. [1] Kostaive was approved for medical use in Japan in November 2023, and it is the first self-amplifying mRNA-based COVID-19 vaccine to be approved. [2] [3]
Coronaviruses exhibit coronavirus spike protein, also known as the S protein, on their surfaces; S is a class I fusion protein and is responsible for mediating viral entry as the first step in viral infection. [10] It is highly antigenic and accounts for most antibodies produced by the immune system in response to infection.
Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant ...
By 2010, in vitro experiments had confirmed that modifications to the spike protein receptor binding domain could enable human infection by several SARS-related coronaviruses. [9] Virologists Rachel Graham and Ralph S. Baric at that time wrote, "that the question of emergence of another pathogenic human coronavirus from bat reservoirs might be ...